Skip to content
10-Q

Quarterly Report

BENITEC BIOPHARMA INC. BNTC

0001193125-26-222885

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2026 · May 4, 2026 34.35M sh
Shares Diluted Q3 2026 · Mar 31, 2026 49.39M sh
Shares Diluted Q3 2026 · Mar 31, 2026 45.6M sh
Shares Diluted Q3 2026 · Mar 31, 2025 38.6M sh
Shares Diluted Q3 2026 · Mar 31, 2025 34.56M sh
Capex Q3 2026 · Mar 31, 2026 $26K
Capex Q3 2026 · Mar 31, 2025 $18K
Operating Cash Flow Q3 2026 · Mar 31, 2026 −$11.58M
Operating Cash Flow Q3 2026 · Mar 31, 2025 −$15.38M
Cash And Equivalents Q3 2026 · Mar 31, 2026 $184.76M
Cash And Equivalents Q3 2026 · Jun 30, 2025 $97.74M
Stockholders Equity Q3 2026 · Mar 31, 2026 $183.33M
Stockholders Equity Q3 2026 · Dec 31, 2025 $187.36M
Stockholders Equity Q3 2026 · Sep 30, 2025 $93.6M
Stockholders Equity Q3 2026 · Jun 30, 2025 $97.3M
Stockholders Equity Q3 2026 · Mar 31, 2025 $97.57M
Stockholders Equity Q3 2026 · Dec 31, 2024 $75.94M
Stockholders Equity Q3 2026 · Sep 30, 2024 $64.18M
Stockholders Equity Q3 2026 · Jun 30, 2024 $47.25M
Current Liabilities Q3 2026 · Mar 31, 2026 $3.27M
Current Liabilities Q3 2026 · Jun 30, 2025 $1.8M
Total Liabilities Q3 2026 · Mar 31, 2026 $3.67M
Total Liabilities Q3 2026 · Jun 30, 2025 $2.3M
Current Assets Q3 2026 · Mar 31, 2026 $186.02M
Current Assets Q3 2026 · Jun 30, 2025 $98.52M
Total Assets Q3 2026 · Mar 31, 2026 $187M
Total Assets Q3 2026 · Jun 30, 2025 $99.59M
Eps Diluted Q3 2026 · Mar 31, 2026 −$0.24
Eps Diluted Q3 2026 · Mar 31, 2026 −$0.72
Eps Diluted restated Q3 2026 · Mar 31, 2025 −$0.38
Eps Diluted restated Q3 2026 · Mar 31, 2025 −$0.84
Eps Basic Q3 2026 · Mar 31, 2026 −$0.24
Eps Basic Q3 2026 · Mar 31, 2026 −$0.72
Eps Basic restated Q3 2026 · Mar 31, 2025 −$0.38
Eps Basic restated Q3 2026 · Mar 31, 2025 −$0.84
Sga Expense Q3 2026 · Mar 31, 2026 $7.28M
Sga Expense Q3 2026 · Mar 31, 2026 $21.26M
Sga Expense restated Q3 2026 · Mar 31, 2025 $8.84M
Sga Expense restated Q3 2026 · Mar 31, 2025 $16.47M
Rd Expense Q3 2026 · Mar 31, 2026 $6.3M
Rd Expense Q3 2026 · Mar 31, 2026 $15.5M
Rd Expense restated Q3 2026 · Mar 31, 2025 $6.5M
Rd Expense restated Q3 2026 · Mar 31, 2025 $15.47M
Net Income Q3 2026 · Mar 31, 2026 −$11.94M
Net Income Q3 2026 · Mar 31, 2026 −$32.74M
Net Income Q3 2026 · Dec 31, 2025 −$11.84M
Net Income Q3 2026 · Sep 30, 2025 −$8.97M
Net Income restated Q3 2026 · Mar 31, 2025 −$14.5M
Net Income restated Q3 2026 · Mar 31, 2025 −$29.11M
Net Income restated Q3 2026 · Dec 31, 2024 −$9.55M
Net Income Q3 2026 · Sep 30, 2024 −$5.06M
Operating Income Q3 2026 · Mar 31, 2026 −$13.58M
Operating Income Q3 2026 · Mar 31, 2026 −$36.76M
Operating Income restated Q3 2026 · Mar 31, 2025 −$15.34M
Operating Income restated Q3 2026 · Mar 31, 2025 −$31.93M
Revenue Q3 2026 · Mar 31, 2026 $0
Revenue Q3 2026 · Mar 31, 2026 $0
Revenue Q3 2026 · Mar 31, 2025 $0
Revenue Q3 2026 · Mar 31, 2025 $0